DCA Vantage AnalyzerDrive diabetic patient compliance with trusted, clinically proven results
The DCA Vantage® Analyzer is a multi-parameter, point-of-care analyzer for monitoring glycemic control in patients with diabetes and detecting early kidney disease.
- CLIA-waived HbA1c test that is IFCC and NGSP-certified
- 1µl finger stick without fasting – HbA1c results in 6 minutes
- Random urine sample provides A:C ratio in 7 minutes
- Requires no sample or reagent preparation prior to testing
- New 2-D bar-code scanner — for the DCA Vantage® Analyzer and CLINIITEK Status® Connect System
Features & Benefits
Easy to use and implement
- Plug and play installation
- Simple, one-step calibration scan with every new lot
- Guided user-interface with step-by-step testing instructions
- Hassle-free maintenance
Improve patient outcomes and operational costs
- Increase patient satisfaction when testing during office visit1
- Aid in lowering HbA1c levels over time2,3
- Reduce costs associated with post-visit testing1
- Satisfy HbA1c and kidney check HEDIS quality measures
Failsafe measures for audit risk mitigation
- QC lockout prevents patient testing if QC not tested or fails
- Prevent unauthorized users from testing and accessing confidential patient information
- Eliminate transcription errors with bar-code data entry and automatic transmission of results
- Link patient results to operators and material lot information (audit-ready)
- Customizable operator-specific system access mode
Results you can trust
- Robust reagent cartridges designed to minimize pre-analytical errors associated with sample and reagent handling
- Consistently meet NGSP and IFCC annual certifications for HbA1c
- Clinically proven to correlate with lab methods4,5
Assays
Hemoglobin A1c (HbA1c)
Albumin
Creatinine
Albumin-to-Creatinine (A:C) Ratio Results
Technical Specifications
Did this information help you?
References
Crocker, et al. Patient satisfaction with point-of-care laboratory testing: report of a quality improvement program in an ambulatory practice of an academic medical center.
Clinica Chimica Acta. 2013;424:8-11.
Schnell, et al. Impact of HbA1c testing at point of care on diabetes management. Journal of Diabetes Science and Technology. 2017;11(3):611-17.
Petersen J, et al. Effect of point-of-care on maintenance of glycemic control as measured by A1C. Diabetes Care. 2007 Mar;30(3).
Felix O. Omoruyi, Gul M. Mustafa, Anthony O. Okorodudu, John R. Petersen. Clinica Chimica Acta 413 (2012) 625–629; evaluation of the performance of urine albumin, creatinine and albumin–creatinine ratio assay on two POCT analyzers relative to a central laboratory method.
Weykamp et al. Clin Chemisty 61:5; 752-759